Teladoc (TDOC) PT Lowered to $8 at Stephens

Stephens analyst Jeff Garro lowered the price target on Teladoc (NYSE: TDOC) to $8.00 (from $9.00) while maintaining a Equal Weight rating.

The analyst commented: "We are updating our model ahead of 1Q25 EPS to align with prior management commentary and formal guidance. Since last quarter TDOC has made progress on its efforts to round out its Integrated Care B2B offering (e.g., Next Generation of Virtually Integrated Care, adding a GLP-1 self-pay option to Comprehensive Weight Care, and introducing a Next Generation CardioMetabolic program), while its DTC virtual mental health business, still faces uncertain over customer acquisition cost trends and demand ahead of fears of economic uncertainty. Reiterate our EW rating, TP moves from $9 to $8."

You May Also Be Interested In

• Netflix eyes Letterboxd acquisition, Variety reports, citing Puck
• UBS Reiterates Neutral Rating on Buckle, Inc. (BKE)
• GLJ Research: 'Sunrun’s AI pilot has no filed economics, no named buyer, and no owner for the GPU decay'